Publication Library
Full access to our published articles
Publication list
(To directly download each PDF file, click on titles, please)
- Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma (Cancer and Metastasis Reviews, 2024) [Q1, Impact Factor= 10]
- Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions (Biomedicines, 2024) [Q1, Impact Factor= 4.7]
- Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates (American Journal of Cancer Research, 2022) [Q2, Impact Factor= 5.3]
- Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress (Gene, 2022)[Q2, Impact Factor= 3.5]
- Comparative mRNA/micro-RNA co-expression network drives melanomagenesis by promoting epithelial–mesenchymal transition and vasculogenic mimicry signaling (Translational Oncology, 2021) [Q2, Impact Factor= 5]
- Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy (American Journal of Cancer Research, 2021) [Q2, Impact Factor= 5.3] {More than 20 times cited}
- Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy (International Journal of Biological Markers, 2021) [Q4, Impact Factor= 2] {More than 10 times cited}
- Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons (Frontiers in Immunology, 2021) [Q1, Impact Factor= 7.3] {More than 70 times cited}
- PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer (Scientific Reports, 2021) [Q2, Impact Factor= 4.6]
- Metagenome Analysis of Intestinal Bacteria in Healthy People, Patients With Inflammatory Bowel Disease and Colorectal Cancer (Frontiers in Cellular and Infection Microbiology, 2021) [Q2, Impact Factor= 5.7] {More than 30 times cited}
- Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma (Frontiers in Immunology, 2021) [Q1, Impact Factor= 7.3] {More than 40 times cited}
- Excessive Intake of Longan Arillus Alters gut Homeostasis and Aggravates Colitis in Mice (Frontiers in Pharmacology, 2021) [Q1, Impact Factor= 5.6] {More than 10 times cited}
- Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis (International Journal of Biological Sciences, 2021) [Q1, Impact Factor= 9.2] {More than 30 times cited}
- m5C RNA Methylation Primarily Affects the ErbB and PI3K–Akt Signaling Pathways in Gastrointestinal Cancer (Frontiers in Molecular Biosciences, 2020) [Q2, Impact Factor= 5] {More than 20 times cited}
- Increased ABCC4 Expression Induced by ERRa Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer (Frontiers in Oncology, 2020) [Q2, Impact Factor= 4.7] {More than 10 times cited}
- Analysis of Key Genes Regulating the Warburg Effect in Patients with Gastrointestinal Cancers and Selective Inhibition of This Metabolic Pathway in Liver Cancer Cells (OncoTargets and Therapy, 2020) [Q2, Impact Factor= 4] {More than 20 times cited}
-
(HOT ARTICLE) Akt-targeted
therapy as a promising strategy to overcome drug resistance in breast
cancer – A comprehensive review from chemotherapy to immunotherapy (Pharmacological Research, 2020) [TOP 10%, Impact Factor= 9.3] {More than 100 times cited}
- CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells (International Journal of Molecular Medicine, 2020) [Q2, Impact Factor= 5.4] {More than 30 times cited}
- Characterization of chemical composition and prebiotic effect of a dietary medicinal plant Penthorum chinense Pursh (Food Chemistry, 2020) [TOP 10%, Impact Factor= 8.8] {More than 30 times cited}
- Lapatinib as a Dual Tyrosine Kinase Inhibitor Unexpectedly Activates Akt in MDA-MB-231 Triple-Negative Breast Cancer Cells (Letters in Drug Design & Discovery, 2020) [Q4, Impact Factor= 1]
- Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy (Pharmacological Research, 2020) [TOP 10%, Impact Factor= 9.3] {More than 30 times cited}
- Conditional reprogramming: next generation cell culture (Acta Pharmaceutica Sinica B, 2020) [TOP 10%, Impact Factor= 14.5]{More than 40 times cited}
- A review of Penthorum chinense Pursh for hepatoprotection: Traditional use, phytochemistry, pharmacology, toxicology and clinical trials (Journal of Ethnopharmacology, 2020) [Q1, Impact Factor= 5.4] {More than 30 times cited}
- Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets (International Journal of Biological Sciences, 2020) [Q1, Impact Factor= 9.2] {More than 20 times cited}
- Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer – contradictory effects and future perspectives (Biomedicine & Pharmacotherapy, 2020) [Q1, Impact Factor= 7.5] {More than 30 times cited}
- Glyoxalase 1 gene improves the antistress capacity and reduces the immune inflammatory response (BMC Genetics, 2019) [Q3, Impact Factor= 2.9]
- Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review (Current Medicinal Chemistry, 2019) [Q2, Impact Factor= 4.1] {More than 20 times cited}
- (HOT ARTICLE) m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer (Translational Oncology, 2019) [Q2, Impact Factor= 5] {More than 100 times cited}
- Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study (Pharmacological Reports, 2019) [Q2, Impact Factor= 4.4] {More than 50 times cited}
- Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment (PLOS ONE, 2018) [Q2, Impact Factor= 3.7] {More than 20 times cited}
- Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs (Recent Patents on Anti-Cancer Drug Discovery, 2017) [Q3, Impact Factor= 2.8] {More than 10 times cited}
- (HOT ARTICLE) MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment (Pharmacological Research, 2015) [TOP 10%, Impact Factor= 9.3] {More than 150 times cited}
- (HOT ARTICLE) Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer (European Journal of Pharmacology, 2014) [Q1, Impact Factor= 5] {More than 150 times cited}
Research Impact
1
Impact Factor
1
h-Index
1
Citations